Speakers – KPJ-Healthcare

KEYNOTE
Healthcare Transformation, Reimagining and Redefining the Future of Healthcare

Datuk Syed Mohamed was appointed to the post of President and Chief Executive, as well as the Board Member of Johor Corporation beginning 9 January 2020.

He holds a Bachelor of Economics in Analytical Economics (Hons) from the University of Malaya. He then attended the Senior Management Development programme in Public Enterprises at Harvard University.

He is also a Board Member of the Sultan Ibrahim Johor Foundation and the Tunku Laksamana Johor Cancer Foundation. In 2021, he was appointed as an Eminent Industry Fellow by Universiti Sains Malaysia via the School of Management as well as an Adjunct Professor of the Faculty of Built Environment and Surveying (FABU) of Universiti Teknologi Malaysia.

Reimagining the Care Economy

After graduating as a medical doctor in 1973, she served as house doctor at University Hospital UM and medical officer at Hospital Kuala Lumpur. In 1975 she joined UKM as a lecturer in Physiology and rose to become head of Physiology and later as founder head and professor of the Medical Education Department.

Among the innovative programmes that were introduced were problem-based learning in the undergraduate curriculum and distance learning in Family Medicine. In 1996 she was appointed as Director of International Relations and later as Director of Strategic Planning and Development at the main campus in Bangi where she played a more central role for university development, including quality assurance.

In 2000 she was appointed as Director of the Division of Quality Assurance, Ministry of Education, tasked with developing the quality assurance system for public universities. While simultaneously serving on the Lembaga Akreditasi Negara Board (LAN) she initiated the accreditation of educational programmes in Medicine, Nursing, Dentistry and Pharmacy. In January 2006 she was appointed the CEO of LAN and completed the formulation of the Malaysian Qualifications Agency Bill, which became the MQA Act in June 2007.

In August 2006 she was appointed as the first woman Vice Chancellor of UKM and served until December 2014. She brought the university to be at par with leading research universities of the same age (40-50 years), while preserving its role in promoting Bahasa Melayu as an academic language. Under her leadership UKM was accorded Self-accrediting status, granted autonomy and was selected as a Research University. During her tenure, UKM was ranked number 23 for world universities below 50 years and 8th in Asia.

UKM was consistently in the top 300 of world university rankings. She changed UKM from a university that had only 180 citations to one that accumulated 16,000 citations within 7 years. Through her leadership and an innovative transformation programme for UKM, she managed to break the academic silos and got faculty to work together in multidisciplinary research groups, focusing on 11 niche areas which supported the National Transformation Programme.

Research productivity increased with more than 800 patents filed and technology transfer for commercialization through 33 start-up companies which generated revenue and created jobs. The basic curriculum was revamped with clear learning outcomes and a compulsory requirement for entrepreneurship where students were assisted to launch companies.

During her tenure more than 100 student companies were incubated and launched at graduation. Her NCWO background heightened her sensitivity to university-community engagement where students and staff were encouraged to transfer knowledge for societal development.

Community engagement was most active at the five regional sites where UKM has a campus (living labs), namely the Langkawi Geopark Research Station, Teluk Intan Community Health Campus, Mersing Marine Research Station, Tasik Chini and Wetlands Research Station and Fraser’s Hill Montane Research Station. In addition UKM adopted two villages in Kundang Hulu, Pagoh and Pulau Manis, Pekan.

As Vice Chancellor, she was tasked by YB Dato Mustapa Mohamed, Minister of Higher Education then to draft the National Higher Education Strategic Plan (NHESP), which served as the blueprint for Higher Education in Malaysia.

In 2011 she was appointed by MOHE to chair the Critical Agenda Project on governance for autonomy. Within a year she produced the Code of University Good Governance (CUGG) and procedures for evaluating the preparedness of IPTAs for autonomy or University Good Governance Index (UGGI). Both documents are used for auditing universities before conferring the status of autonomy. She also served as Chairperson of the Vice Chancellors’ Committee.

Upon her retirement as Vice Chancellor of UKM she was appointed as Senior Consultant to the Prime Minister’s Department (2014-18) and tasked to oversee the PERMATA programmes which she helped to develop as Vice Chancellor. The programmes include early childhood education (PERMATA Negara), two schools for the Gifted and Talented (PERMATA Pintar at UKM and PERMATA Insan at USIM), Empowerment programme for Youths-at-Risk (PERKASA Remaja), Centre for children with autism (PERMATA Kurnia) and the PERMATA Children’s Hospital at UKM.

She was appointed as KPJ Healthcare University’s Chancellor in 2023.

POCKET TALK
Anjeon Smart-Clip: An Innovation for Identifying Colorless Solution Used During Surgery in KPJ Seremban Specialist Hospital

POCKET TALK
The Effectiveness of Quick Response (QR) Code in Helping Patients of KPJ Penang Specialist Hospital for Home Exercise Programme (HEP) at Physiotherapy Services

POCKET TALK
Continuous Positive Airway Pressure (CPAP) in Preterm & Term Neonates

PLENARY 1
How Digital Transformation and AI Influences Person-Centered Care

Michael is the Chief Operating Officer at Planetree International, a mission-driven non-profit setting the global standard for person-centered excellence across the continuum of care. Michael joined the organization after nine years of healthcare management work in Australia.

Most recently, he was the Executive Director of the international and consulting divisions of The Australian Council on Healthcare Standards (ACHS) working across Australia and 15 countries in the Middle East and Asia Pacific to support improvements in safety, quality, and outcomes.

During his tenure, Michael led the development of standards focused on person-centered care and systems to encourage healthcare organizations to improve services for patients, staff, families, and surrounding communities.

Previously, Michael worked at St. John of God Healthcare in Melbourne leading complex transformational programs such as division divestments and workforce optimization.

He received his Masters in Healthcare Policy and Financing from London School of Economics and is pursuing a PhD from the University of Cambridge exploring the impact of person-centered care implementation on outcomes and healthcare value.

PLENARY 2
Improving Patient Experiences Based on Digital Transformation with the Seamless Blend of ‘Digital Tech’ with ‘Human Touch’

Associate Prof. Dr. Son currently serves as an Emergency Care Center Deputy Director and Clinical Instructor, Department of Paediatrics at Samsung Medical Centre, Seoul. Associate Prof. Dr. Son graduated with Medical Degree from Gyeongsang National University and holds Master of Medicine (Paediatrics) from the same university.

LUNCH TALK
Data Assetization: Unlocking the True Value of Medical Data with INFINITT Healthcare Platform

Mr. Park is a Senior Business Development Manager with 15+ years of experience in the medical imaging software industry. Proven ability to generate new leads, build relationships with key decision-makers, and close deals in a highly complex and competitive market. Expertise in lead generation, sales strategy, negotiation, account management, customer relationship management, and channel management. Mr. Park holds a Bachelor Degree in Business Administration – IT from Symbiosis International University, India.

Data is the New Gold

Data is the new gold in this digital age we live in. Enterprises and countries around the world build strategies and make important decisions based on insights gained from data. The healthcare sector is no exception either. While compliance to patient privacy is one of the core challenges of big data in healthcare, an increasing number of authorities are adjusting the details of privacy policies to enable wider use of medical data in clinical care and research.

Changing Perspective on Data and its Usages

There are three steps to the process of data assetization:

Digitalization
Consolidation
Utilization

Step 1 | Digitalization
The first step is the digitalization of all departmental data. Just like sharing the same language helps us communicate more effectively with each other, data also needs to be in the same ‘digital format’ to connect more seamlessly with data from other departments. While digitalization sets the foundation for the entire data assetization process, it offers a lot of merits on its own as well.

Step 2 | Data Consolidation
Then comes data consolidation. Bringing data together through consolidation leads to patient centric use of data. Physicians often refer to data from other departments when diagnosing diseases or treating patients. The consolidation of all departmental data enables them to easily access whatever data they need in real time and deliver care from a more holistic perspective.

Step 3 | Data Utilization
Once the data has been digitalized and consolidated, it’s now time to take full advantage of its potentials.

1. Real-Time Data Sharing

In an emergency situation, timely treatment could mean life or death for the patients. For example, when transferring a trauma patient in an ambulance, the emergency medical technicians (EMTs) can capture and upload the status of trauma conditions and other vital signs data (ECG, blood pressure, oxygen saturation levels, etc.) to your hospital, then medical team back at the hospital can then quickly check the severity of trauma conditions using an enterprise viewer and make preparations for timely treatment prior to patient arrival.

2. Streamlined MDT Workflow

Multidisciplinary team (MDT) care is one of the most patient-centric ways of diagnosing and treating patients with complex diseases like cancer. MDT-participating physicians from each specialty can now prepare materials for future MDT meetings with just a click of a button while reviewing patient exams on each of INFINITT’s departmental solutions like INFINITT PACS and INFINITT Digital Pathology Solution. Then on the day of the MDT meeting, they can discuss patient conditions from a more holistic perspective while viewing a pre-uploaded set of patient data on INFINITT MDT viewer. Because the entire MDT workflow is streamlined through data digitalization and consolidation, it becomes easier for the physicians to delve straight into in-depth discussions on what’s best for each patient.

3. Less Managerial Resources

Assetized data is easier to manage in many ways. Before, each department used to manage its own server and storage which resulted in a lot of costs and resources for the hospital as a whole. But now with INFINITT Fault Prevention Solution (INFINITT FPS), hospital IT managers are able to centrally manage and monitor all of INFINITT’s departmental solutions, servers, and storages from a single point of access. In the end, the assetization of data strengthens the continuity of system operations and data management throughout the hospital and helps build a more stable clinical environment.

4. Virtuous Cycle of Medical Data

Data assetization enables hospitals to create a virtuous cycle of medical big data. Clinical data collected from over the course of patient care is consolidated, classified and processed (cleansed, labelled, anonymized, pseudonymized, etc.) into research datasets through IHP. These datasets can then be used to reduce the duration and cost of clinical trials, to develop new Al algorithms for preventive medicine and more. The insights or technologies gained from these research projects are re-applied to clinical practices, and the following patient outcomes are then used as the basis for research again.

Your Strategic Partner, INFINITT Healthcare

Hospitals with a systematic data strategy will be the ones to lead the future healthcare market. It’s only natural because a systematic data strategy lays the foundation for securing higher quality data and making use of that data for more advanced studies, which ultimately results in being able to provide better quality care. In order to successfully assetize your departmental data at an enterprise scale, you need a strategic partner with high expertise in data management and system interfaces. With over 20 years of experience in the field of healthcare digitalization and data integration, INFINITT Healthcare can be a strategic partner in your journey to unlocking the true value of data at your hospital.

SYMPOSIUM 1 Impact of Digital and Technology in Healthcare
What Keeps Us Awake at Night?

Mohamed Ridza Abdulla is now the managing partner of Mohamed Ridza & Co, a legal 500 boutique corporate law firm based in Kuala Lumpur, Malaysia. Prior to opening the firm, Ridza was a partner and was head of his division with Zaid Ibrahim & Co.

Ridza graduated with a LLB (First Class Hons) from the International Islamic University Malaysia in 1992 and was called to the Malaysian Bar in 1993. He began his career as a corporate finance and projects lawyer at the firm of Rashid & Lee in Malaysia. He later joined Arab Malaysian Corporation Berhad as the group legal adviser.

Being the group legal adviser, he was instrumental in setting up the legal department of the Amcorp Group of Companies. Ridza left Arab Malaysian to become the General Legal Counsel of Technip Asia Pacific based in Kuala Lumpur and was previously attached at Technip headquarters in Paris, France.

Ridza is a Fellow of the Institute of Chartered Secretaries and Administrators (FCIS), an Associate Member of the Chartered Institute of Arbitrators (ACI Arb) and a Fellow of Malaysian Society of Adjudicators. He is an accredited mediator with the Bar Council at Malaysia, a certified adjudicator and also a panel arbitrator with the Kuala Lumpur Regional Centre of Arbitration in the area of Islamic Banking & Finance.

He has advised on a wide variety of corporate, financing in particular Islamic finance and capital markets and commercial matters including mergers and acquisitions of listed and non-listed entities, listings of public companies, joint venture and consortium agreements involving foreign and multinational companies, venture capitalist transactions, capital markets and real estate projects. He also advises broadly on major state and federal privatisation projects particularly in the oil and gas industry and property development.

Ridza also specialises in technology, telco and fintech related contracts and acquisitions. He has presented many papers in conferences on areas relating to corporate governance, financing, capital markets, technology, fintech, digital transformation, S17A MACC, mergers and acquisitions. Ridza achievements have ranked him as a one of the top 100 lawyers in Malaysia for 3 years in a row by Asia Business Journal.

Ridza also sits as an independent director on the board of several public companies and also their respective audit committees. He chairs the board technology committee of a bank and is involved in the setting up of the bank’s digital banking business. At another public listed company, Ridza chairs the board risk committee and oversees the company’s technology and digital business.

In addition, Ridza is also the author of several publications including: The Law and Practice of Islamic Banking & Finance (now in its 3rd edition); and The Life and Law of Fintech published by Sweet & Maxwell.

At the international scene, Ridza has advised clients in Singapore, the Middle East, the Philippines, Canada, Brunei, Indonesia, Myanmar, Turkey, Morocco, Libya, the USA, Lebanon, Australia and Europe.

SYMPOSIUM 1 Impact of Digital and Technology in Healthcare
Digital Informed Consent, Telemedicine Legal Development

Fahri Azzat has been in legal practice since August 1999. He conducts litigation over wide and diverse areas of law which include tortious, contract, corporate, criminal, industrial, family, constitutional, administrative and Syariah areas of law. He is the author of the Malaysian Guide to Advocacy (Sweet & Maxwell, 2019) and is presently a member of the Malaysian Bar Council.

SYMPOSIUM 2 Impact of Digital and Technology in Healthcare
Enabling Value-based Care in Hospitals Through AI

Dr. Lutfi is the founder and CEO of Valiance Health, a health tech start-up providing solutions to enable value-based care in health systems using AI. From 2013 to 2017, he served the Ministry of Health Malaysia as a house officer at Sungai Buloh Hospital and later as a health economics researcher at the Institute of Health Systems Research.

He received several international recognitions, including Forbes 30 under 30 and United Nations Young Leader for Sustainable Development Goals. Dr. Lutfi received his MD from the National University of Malaysia (UKM) in 2012 and completed his doctorate at Harvard University in 2020.

In today’s healthcare landscape, hospitals are inundated with an unprecedented influx of data, far surpassing their capacity to effectively manage and analyze it. Institutions find themselves grappling with the challenge of extracting meaningful insights from this vast pool of information to enhance patient care and streamline operations.

This talk will explore the pressing need for artificial intelligence (AI) solutions to enable a transition towards value-based care in healthcare settings as it offers hospitals the means to shift from a reactive, fee-for-service model to a proactive, value-based care paradigm.

By deploying machine learning algorithms, predictive analytics, and natural language processing, hospitals can identify patterns and trends within patient data, enabling early disease detection, personalized treatment plans, and improved patient outcomes and ultimately achieve the holy grail of modern healthcare – delivering better care at a lower cost.

SYMPOSIUM 2 Impact of Digital and Technology in Healthcare
Cost of Acute Stroke Care at A Private Hospital: Patient’s Perspective

Professor Dr. Tan Ching Siang is a Malaysian registered who holds an academic position at KPJ Healthcare University. He completed his undergraduate studies in Pharmacy at the UM, followed by a Master of Science degree in Pharmaceutical Policy and a Doctorate in Clinical Pharmacy at USM. Furthermore, he obtained the Medical Certificate in Clinical Hypnosis program at the London College of Clinical Hypnosis and Certificate of Pharmacoeconomic Distance Learning Module from International Society for Pharmacoeconomics and Outcomes.

In the year 2006, he completed his provisional registered pharmacist training at Penang General Hospital. Subsequently, he worked as an ICU clinical pharmacist at Seberang Jaya Hospital before transitioning his role as a community pharmacist. In 2013, Professor Tan embarked on an academic career, driven by his dedication to research and teaching.

His dedication to excellence in healthcare has earned him numerous accolades and recognition from peers and institutions alike. In year 2019, he was appointed as Dean, School of Pharmacy, KPJ Healthcare University College.

As a renowned expert in public health, clinical pharmacy, health economics and pharmacy related research, Professor Tan’s work has had a profound impact on the healthcare landscape in Malaysia and beyond. He has authored and co-authored with 70 international publications. These publications include notable research papers that have been published in esteemed journals such as the Annals of the Academy of
Medicine Singapore, Value in Health Regional Issues, Springer International Publishing, and the Journal of Pharmaceutical Policy and Practice and others.

In addition, Professor Tan is appointed as an executive editorial board member and reviewer for various international research journals, including BMC Health Services Research, Journal Pharmaceutical Policy and Practice, International Journal of Health Economics and Policy, PLOS ONE Journal and etc.

Professor Tan has successfully secured several research grants which include two national grants (specifically, the MyCC award on national pharmaceutical pricing), two industry-based research projects (one focused on community pharmacy and another on hospital clinical trial research project), as well as 6 research grants from university.

In addition, he received an invitation to participate in the WHO Pharmaceutical Price Setting Mechanism Meeting held by Bahagian Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia in year 2016.

In terms of teaching and dissemination of research findings, he continually gives presentations and produce comprehensive reports for the grant funders. He has delivered numerous oral and poster presentations at both international and national conferences and seminars.

Of note, Professor Tan presented the commentary article on “Public and private sectors collective response to combat COVID-19 in Malaysia” in ASEAN Working Group Meeting: NACT Working Group Meeting on Public-Private Partnership in 30-Year ASEAN-China Public Health Cooperation.

Furthermore, Professor Tan demonstrates a strong dedication to community health initiatives and participated in multiple outreach programs focused on enhancing health accessibility and promoting awareness among marginalized populations.

Notably, Professor Tan has served as an invited speaker for Ai-FM Radio Interview Sharing Session, where the discussion centred on the establishment of a smoke-free society. Additionally, Professor Tan was invited to speak for Federation International Pharmaceutical (FIP) Digital Event in 2023, addressing the crucial role of pharmacists in tobacco cessation efforts.

SYMPOSIUM 2 Impact of Digital and Technology in Healthcare
Genomics and AI

Prof. Datuk Dr. A. Rahman A. Jamal is a professor of paediatric haematology, oncology and molecular biology at Universiti Kebangsaan Malaysia. He is the senior principal research fellow of the UKM Medical Molecular Biology Institute (UMBI) and an honorary professor at the University of Dundee, Scotland, UK. He is the project leader for The Malaysian Cohort and the Cohort Biobank which is the largest in South-East Asia, with data and biospecimens from 120,000 participants.

He was the project director for the UKM Specialist Children’s Hospital (2010-2019) and the Pro Vice-Chancellor for the UKM Kuala Lumpur campus (2017-2021). He was a member of the Majlis Hospital Canselor Tuanku Muhriz (equivalent to a hospital board) from 2014-2021 and a board member for the UKM Specialist Centre (2017-2021).

His research interests include cancers, other non-communicable diseases, molecular epidemiology of Covid-19 and cohort studies. He has 220 indexed publications and an H-index of 29. He has supervised 23 PhD and 50 MSc students.

He was chief scientist for the National Angkasawan Programme (2006-2007). He leads the genome research team in UMBI and the team has performed whole genome sequencing on cancers and other diseases. He has completed the Cancer Genome Atlas Malaysia project for colorectal cancer.

His latest project is the Cov-Gen study to investigate host factors that determines the severity, outcome and long-term complications of Covid-19 infection. He is involved in two MRC UK-Malaysia research projects on diabetes and obesity. He is the chairman of National Stem Cell Committee for Ethics in Research and Therapy, Ministry of Health (MOH) and member of the National Clinical Trials Committee MOH.

He is a fellow of the Academy Sciences of Malaysia and heads a task force for the Precision Medicine Initiative. He is currently a board member for the Clinical Research Malaysia Sdn Bhd, Melaka Biotechnology Corporation and NanoMalaysia Berhad.

He is a member of the Wellcome Trust UK Funding Committee for Longitudinal Population Studies, International Health Cohort Consortium (IHCC), and the International Commission for Human Germline Genome Editing (National Academy of Sciences USA and Royal Society UK).

He has given more than 180 invited lectures including plenary and keynote lectures. During Covid-19 pandemic, he is the chairman of the task force for the MOHE-MOSTI collaboration for Covid-19 testing labs in the universities and the leader of the Covid-19 Genome Surveillance project under MOSTI-MOH-MOHE.

SYMPOSIUM 3 Research Innovation
Building The Research Culture and Environment

Prof. Emeritus Dato’ Dr. Lokman Saim is the Vice Chancellor of KPJ Healthcare University, Malaysia. He is an ENT surgeon, with sub- specialization in Otology and Neurotology. His clinical practice is at KPJ Tawakkal Specialist Hospital, Kuala Lumpur. He was formerly Professor of Otorhinolaryngology and Dean Faculty of Medicine and Director of Universiti Kebangsaan Malaysia Medical Center.

Prof. Lokman Saim is amongst the pioneer in cochlear implant surgery in ASEAN and Asia Pacific region. He is appointed as consultant surgeon to establish ear and hearing centers and to perform cochlear implant surgeries in Brunei Darussalam, Jakarta Indonesia, Lahore and Karachi Pakistan and Ho Chi Minh City and Hanoi, Vietnam. To date, he has performed and assisted in more than 1,000 cochlear implant surgeries.

He received his Medical Degree from Universiti Kebangsaan Malaysia in 1984 and his Master of Surgery (ORL) from Universiti Kebangsaan Malaysia in 1991. He obtained his Fellowship of the Royal Colleges of Surgeons Edinburgh in 1989. He did Fellowship in Otology and Neuro-otology at Harvard Medical School, Boston USA in 1993-1994.

He was appointed Clinical Professor at the School of Advanced Medicine, Macquarie University Sydney 2010- 2013. He was conferred Emeritus Professor by Universiti Kebangsaan Malaysia in 2018.

SYMPOSIUM 3 Patient Experience
Management of Glottal Dysplasia and Early Carcinoma

Dinesh Chhetri, MD, is a Laryngologist whose medical practice is devoted to voice disorders, swallowing disorders, upper airway breathing disorders. He graduated from UCLA David Geffen School of Medicine, where he continued his training in Head and Neck Surgery and Fellowship in Laryngology.

He is currently Professor and Vice-Chair in the Department of Head and Neck Surgery at the David Geffen School of Medicine. He serves as the director of the UCLA Laryngology Fellowship and Swallowing Disorders Program and leads the UCLA Head and Neck Cancer Survivorship and functional preservation program.

He is certified in head and neck robotic surgery and is recognized as a specialist in complex airway surgery. Dr. Chhetri’s research has been consistently funded by the National Institutes of Health and he is known nationally and internationally for his clinical and research contributions in the arenas of voice and swallowing disorders. He is passionate about training surgeons throughout the world and has led many international medical missions.

SYMPOSIUM 3 Research Innovation
Mechanical, Medical Imaging and Radiation Properties of Computed Tomography-Based Kidney Phantom Exploiting Textural Analysis

Assoc. Prof. Dr. Izdihar Kamal is a full-time lecturer at KPJ Healthcare University College under Medical Imaging Department since 2010. She obtained her Phd in the field of medical imaging with the research title ‘Mechanical, Medical Imaging And Radiation Properties of Computed Tomography-Based Kidney Phantom Exploiting Textural Analysis’.

Besides, within 30 months of study Dr. Izdihar Kamal had won gold in Mass chapter 2021 in UPM, best paper award for radiomic study in ICOTEN 2021 organized by IEEE and won 2nd place in KPJ Conference 2019. An outstanding achievement she obtained was best presenter in ACEH Conference and best poster in Malaysian Society Radiographer Conference 2022.

Finally she graduated with two papers Q1 and two papers Q2 and few SCOPUS articles. Dr. Izdihar Kamal graduated from UKM in Master of Health Science (Diagnostic Imaging) in 2013. She has 4 years of clinical experience as a Cardiac Angiographer in National Heart Institute (IJN).

Her area of expertise is Invasive Cardiovascular Laboratory procedures, CT scan and material science polymer based. She has published numerous research articles on breast cancer, Polydimethylsiloxane (PDMS) in various high indexed journal and SCOPUS. She has been with KPJUC since July 2010 and is currently the Deputy Dean School of Health Sciences.

POCKET TALK
Implementation of Lean in STEMI Management and Primary Percutaneous Coronary Intervention (Primary PCI) Process Flow in KPJ Selangor Accident & Emergency Department

Sumaria Abd. Moin graduated with a Diploma in Nursing in 1998 from University Science Malaysia, Kubang Kerian. She specialized in Paediatric Nursing in 2004, HKL and pursued the Certificate in Management and Leadership in year 2007 and Bachelor in Nursing in 2010.

She has worked as a paediatric nurse in KPJ Selangor Specialist Hospital since 1998 and was later promoted as Unit Manager of the Paediatric Ward in 2007. She was appointed as Quality Manager by KPJ Selangor in 2013. The following year, she was appointed as the Deputy Chief Nursing Officer and subsequently promoted as Chief Nursing Officer in 2016 till now.

Throughout her employment, she has actively been involved in various clinical and improvement activities such as participating in innovation projects and poster competitions at the KPJ Group level, national as well as international level.

POCKET TALK
Implementation of Ventilator-Associated Events (VAE) Bundle Checklist to Decrease Ventilator-Associated Pneumonia, Among Ventilated Patients In ICU KPJ Ampang Puteri Specialist Hospital

Adam Lutfi Abdul Nasir graduated from the International Islamic University Malaysia in 2021. With a Bachelor of Nursing (Hons.) under his belt, he joined KPJ Ampang Puteri Specialist Hospital where he recently represented his hospital at the International Society for Quality in Healthcare (ISQua) 2023 Seoul Conference.

POCKET TALK
Good Catch Initiative to Prevent Medication Error

Nurul Afiqah Heffny obtained her Bachelor in Pharmacy (Hons) from School of Pharmacy, KPJ Healthcare University College (KPJUC) in year 2017. She graduated from Diploma in Pharmacy, Universiti Teknologi Mara (UiTM) in year 2014 receiving Vice-Chancellor’s Award.

Being a Malaysian Full Registered Pharmacist (Reg No: 017937) since 2019, she has completed the compulsory hospital services in KPJ Ampang Puteri Specialist Hospital.

To extend her skill and knowledge, she has undergo Medication Safety Specialist Program for 1 full year in 2022 by International Society for Quality in Health Care (ISQua). She works as a pharmacist in KPJ Ampang Puteri Specialist Hospital since 2018 and in charge of in-patient pharmacy since 2019. She initiated Good Catch Initiative since 2019 until present.

PLENARY 3
Precision Surgery: The Next Leap Forward for Our Patients

A highly renowned surgeon, scientist, and educator, Dr. St. John is Professor and the Chair of Department of Head and Neck Surgery and Professor of Bioengineering at UCLA. She also holds the Thomas C. Calcaterra, M.D., Chair in Head and Neck Surgery and is Co-Director of the UCLA Head and Neck Cancer Program.

Dr. St. John’s laboratory studies the mechanisms of tumor progression and metastasis in head and neck cancer and seeks to identify and study novel genes and pathways for future targeted therapies, while actively incorporating the results of their laboratory-based research into the development of novel therapeutics. Her extramurally-funded research portfolio includes multiple NIH grants bridging basic science with clinical research and service.

Dr. St. John is an outstanding educator who has provided mentorship to numerous trainees and serves as a member of several prestigious organizations including the Executive Council of the American Head and Neck Society, Nominating Committee of the Triological Society, American Academy of Otolaryngology-Head & Neck Surgery, American College of Surgeons Board of Governors Advisory Council, and American Laryngological Association.

She also is a senior examiner for the American Board of Otolaryngology and a reviewer for the American Academy of Otolaryngology/Head and Neck Surgery CORE grants, and NIH/NIDCR, NCI and NIBIB study sections. She has been the recipient of multiple awards for teaching and research.

Dr. St. John received her B.S. from Stanford University and M.D. and Ph.D. degrees from Yale University. She completed residency and postdoctoral training at UCLA and served previously as Chief of Head and Neck Surgery at Harbor-UCLA Medical Center.

Dr. St. John’s clinical expertise is in intraoperative tumor margin delineation in the resection and treatment of head and neck cancers to allow for precision surgery. Her laboratory research is translational with a focus on improving therapies and outcomes for patients with head and neck cancer. Her efforts have helped in the development of strong interdepartmental research programs in Head & Neck Surgery and Bioengineering. This work has led to clinical trials and patent applications and has been consistently funded by the NIH, charitable foundations, and industry.

In addition to maintaining a busy surgical practice, Dr. St. John is active in clinical research and is closely involved in training young physician-scientists in her role as Executive Director of Cancer Research and Education at the Jonsson Comprehensive Cancer Center.

She is a prolific author in head and neck medicine and a sought-after lecturer both nationally and internationally. Dr. St. John has a deep passion for international collaboration in clinical care, research and education and has set up partnerships in Central America, India, China and the Middle East.

She has served on numerous editorial boards of several international journals, including Cancer, Clinical Cancer Research, Head & Neck and The Laryngoscope.

Dr. St. John has consistently been named one of America’s Top Doctors by the Castle Connolly Guide.

PLENARY 5
Leadership Dynamics for Healthcare Transformation

Recently retired as the EVP & CEO Downstream of PETRONAS on 1 January 2022, Datuk Md Arif had an illustrious career with more than 37 years of experience in the integrated oil and gas industry.

Holding a Bachelor of Science in Electrical Engineering from Boston University, USA, and Masters of Business Administration from Massachusetts Institute of Technology (MIT), USA, Datuk Md Arif has held various senior management positions within PETRONAS Group including, the CEO of ASEAN Bintulu Fertilizer (ABF), Senior General Manager (Retail Business) of PETRONAS Dagangan Berhad and General Manager of Gas Processing Plant (Complex, Petronas Gas Berhad).

LUNCH TALK
How Digital Transformation and AI are Empowering Nurses and Clinicians

Andy has 21 years in Healthcare IT, helping Hospitals and Healthcare providers on their Digital Transformation Journey. Identifying their key challenges in Patient Experience, Clinical Excellence and Operational Efficiency and collaborating to architect digital transformation and solution roadmaps to achieve key outcomes.

With board solution appreciation for health and trained in Design Thinking he brings empathy, problem analysis, solutioning and value engineering along with passion to achieve outcomes. Having started his career in UK and working for 10 years in Australia and now 18 years based in Singapore, he has a solid grounding of the local healthcare market and culture.

SYMPOSIUM 5 Medical Informatics and AI Shaping Our Tomorrow
Clinical and Industry Perspective

Dr. Steven Wong Bak Siew is the Clinical Associate Professor at Duke NUS Medical School, Singapore. Dr. Wong is the Head of Radiology and Senior Consultant Radiologist at Sengkang Hospital, Singapore.

Dr. Wong’s expertise is in Spinal, Musculoskeletal and Sports Radiology and his research interests includes imaging of Articular Cartilage, Degenerative Joint Diseases and imaging informatics. He is in-charge of the Radiology Informatics for Sengkang General Hospital.

Dr. Wong’s Professional Appointments and Committee Membership includes:

Singhealth Radiological Sciences Academic Clinical Program – Academic Vice Chair, Strategy, Transformation, Innovation and Informatics
Chair, Singhealth RISPACS Steering Committee
Vice President, College of Radiologists, Singapore
Member, Board of Examiners for Masters of Medicine (Radiology), NUS
President, Asian Musculoskeletal Society
ExCo, Co-Chair, Global Outreach Committee, SIIM – Society of Imaging Informatics in Medicine
Member, SIIM Annual Meeting Organising Committee
ExCo Member, Asian Cartilage Repair Society
Member, Education Committee, Asian Oceanic School of Radiology
Member of Scientific Programme Committee for several radiology conferences, including the Singapore Congress of Radiology 2019 and 2020, Radiology Asia 2017 and 2018 and the 2019 and 2020 Annual Scientific Meeting of the Asian Musculoskeletal Society

Our healthcare environment today is having to cope with multiple demands and challenges. Workload and the complexity of the workload – clinical and non-clinical – have increased. The expectations of patients and healthcare professionals have also risen, often times exceeding existing or future capability and capacity.

At the same time, there are advances in Medical & Imaging Informatics and AI, seemingly promising to revolutionise the way we work and manage patients. To fully capitalise on Medical and Radiology AI, there is a strong need for a robust and stable Medical and Imaging informatics environment.

This session provides a clinical and industry perspective on how informatics and AI is shaping, redefining and disrupting our tomorrow. With massively increasing data volumes, new developments in medical innovation including artificial intelligence (AI), and associated hype and hope: there are unique demands posed on your fast evolving imaging ecosystem.

The real challenges the clinical teams and the diagnostic sciences teams encounter
The industry’s & R&D team’s responses.

Adaptability of solutions to fit clinical practice and workflow is discussed and a “one size fits all” solution may not be the best future proof option.
The session has a special focus on the value of clinical insights gained from medical informatics and AI as part of the end-to-end clinical imaging workflow, and how this is helping the healthcare professionals accelerate productivity and increase patient benefits.

No matter where your organisation is on your unique medical informatics journey, this session will provide valuable insights, challenges and examples of both success and lessons learnt through their medical informatics and AI experience.

SYMPOSIUM 5 Medical Informatics and AI Shaping Our Tomorrow
Clinical and Industry Perspective

Dr. Shrestha has 30+ years’ experience, proven breadth and depth of domain expertise, in medical imaging and international healthcare informatics – market, technology, trends. Proven track record and leadership ability as co-founder, Executive Leader, General Manager and Vice President.

Healthcare executive with successful track record in securing, contracting and leading delivery of large, complex medical programmes (inc. winning US$55m diagnostic imaging contract).

PhD in Medical Imaging Informatics and Business Management from Imperial College London as a Massachusetts Institute of Technology (MIT) Scholar for global consortium developing DICOM and HL7 standards in medical Information Systems.

Author of multiple peer-reviewed papers and holder of patents related to imaging, medical standards and medical devices.

Confident delivering internationally, at Executive/Board and senior management levels.

Corporate development inc. M&A, IPO, alliance management and international relationships.

Passion for making a difference with innovative healthcare solutions in everyday clinical workflow, especially in growing markets.

Whilst industry can provide solutions, there is a need to collaborate closely with Healthcare Professionals and Leadership to locate the pain points, the inefficiencies and inadequacies present in the healthcare environment. There needs to be close collaboration and coordination between:
i. The real challenges the clinical teams and the diagnostic sciences teams encounter
ii. The industry’s & R&D team’s responses.

SYMPOSIUM 6 Clinical Niche 1
Advanced Cellular Therapeutics: The Way Forward in Malaysia

Prof. Dr. Tunku Kamarul Zaman is presently the director of University of Malaya Medical Centre (UMMC), a premier university hospital in Malaysia with 1,300 beds and staffed by over 5,000 personnel.

He is by profession an orthopaedic surgeon with special interest in upper limb and microsurgery. He graduated with an M.D. from the National University of Malaysia in 1998. After serving the Ministry of Health as a medical officer for several years, he entered the Masters of Orthopaedics speciality training program i.e. M.S.(Ortho) from University of Malaya and graduated in 2004. He also received a diploma in tissue banking from the National University of Singapore in 2003 during his specialist training.

He then pursued his sub-specialty training in University of Liverpool, UK from 2005 till 2009, and was also awarded a PhD degree from this University. He is presently registered with medical councils in the UK and Malaysia. He is actively involved in basic science orthopaedic related research and is the head of the tissue engineering group, which, is a part of the National Orthopaedic Centre for Research and Learning (NOCERAL) in Malaysia.

He is also the director for the Clinical Investigative Centre in UMMC, an internationally award winning centre that conducts over 200 clinical trials a year. His previous administrative duties also include the deputy dean of research for faculty of medicine, acting dean for faculty of medicine, deputy director (clinical) for UMMC and, head of research in NOCERAL.

His research interest ranges from biomechanics to cell biology, and fundamental research involving cartilage biology and stem cell applications. He has published over 100 peer-reviewed articles in many peer-reviewed journals and supervises many post-doctoral, doctoral and other post-graduate as well as undergraduate students. He sits in many national academic committees, a member of many international societies, have been invited to speak in many international meetings, a reviewer to a number of academic journals and is the editor-in-chief of The Journal of Health and Translational Medicine.

He has received many awards and was awarded the title of Professor from Universiti Malaya in 2011. He has since then been nominated and appointed as an adjunct and honorary professor in several other local and international universities.

SYMPOSIUM 6 Clinical Niche 1
The First Cervical Insufficiency Centre in Malaysia

Dr. Imelda Balchin is a Consultant Specialist in Obstetrics & Gynaecology at Damansara Specialist Hospital 2, who has a Subspecialist Accreditation in Maternal & Fetal Medicine from RCOG UK. In 2014, she was a consultant in Maternal & Fetal Medicine in the UK.

She returned to Malaysia to take on a position as a professor in Maternal & Fetal Medicine in University Malaya. In addition she has a Masters degree in Public Health and was previously a clinical lecturer at the Department on Public Health University College of London. She has published research in preterm birth and stillbirths and her clinical work focuses on prevention of adverse outcomes in pregnancy.

She is also a social media influencer in health with 600K followers on Facebook. In 2018, she was awarded best health advocate in social media by Kementerian Kesihatan Malaysia.

SYMPOSIUM 7Clinical Niche 2
Precision Radiotherapy for Prostate Cancer at KPJ Damansara Cancer & Radiosurgery Centre: SBRT

Dr. Aminudin graduated from the University of Malaya in 1999. He has formal training in clinical oncology overseas (UK, Ireland and Canada) as well as over 20 years’ experience treating cancer patients.

He did his postgraduate training in Clinical Oncology in St Luke’s Hospital, Dublin, Ireland, the National Cancer Centre in Ireland. He obtained the Fellowship of the Royal College of Radiologists (UK) in Clinical Oncology in 2006. He later worked as a Research Registrar under Professor John Armstrong, St. Luke’s Institute of Cancer Research, and was involved in EORTC and ICORG (Irish Clinical Oncology Research Group).

He continued his training and research in radiation oncology as a Clinical Research Fellow in the British Columbia, Vancouver Island Centre, Victoria, British Columbia, Canada under Professor Ivo Olivotto, Head of Radiation Oncology, BCCA (2007-2008). Here, he was involved in RTOG and NCI Canada clinical trials in partial breast radiotherapy and breast IMRT. He also received training in IMRT/IGRT especially in head and neck cancers and formal training in prostate brachytherapy with LDR iodine seeds in the BCCA Vancouver Cancer Centre, which has the largest prostate brachytherapy programme in Canada. As part of the training, he had the opportunity to attend the Seattle Prostate Institute Prostate Brachytherapy Course, Seattle, Washington.

At the end of 2008, he came back to Malaysia and was appointed Consultant Clinical Oncologist in the Department of Radiotherapy & Oncology, Kuala Lumpur Hospital (HKL), the National Tertiary Referral Centre of Malaysia. Here, he was involved in the multidisciplinary care of cancer patients, especially in breast, colorectal, gynaecological, head & neck, prostate & genitourinary cancers and CNS tumours. He was instrumental in starting the IMRT/IGRT services including organising the first National Workshop on Head & Neck IMRT/IGRT and was involved in the SRS programme for intracranial lesions in HKL.

He was a member of the National Committee for Malaysian Guidelines on Radiation Protection in Permanent Prostate Brachytherapy, Ministry of Health, Malaysia. In late 2011, he was appointed an Associate Professor of Medicine (Oncology) in the Faculty of Medicine, University Technology MARA (UiTM), before joining KPJ Johor Specialist Hospital as Consultant Clinical & Radiation Oncologist in 2012. In 2017, he joined KPJ Damansara Specialist Hospital as a resident consultant.

He has published articles in major international peer-reviewed oncology journals and presented at major international oncology meetings in the USA and Canada (ASTRO & CARO). Dr. Aminudin is actively involved in medical societies and cancer-related NGO’s. He is a life member of Malaysian Medical Association (MMA), Malaysian Oncology Society (MOS), Islamic Medical Association Malaysia (IMAM), Academy of Medicine (AM), international member American Society for Therapeutic Radiology and Oncology (ASTRO). He is actively involved in raising cancer awareness in the community through health talks and the media, and through articles in local newspapers and magazines.

He has a special interest in medical health tourism and has given talks to the international community in Malaysia, Indonesia and Vietnam through the Malaysian Healthcare Travel Council (MHTC) and the KPJ Group. He is a Visiting Consultant Clinical Oncologist at the KPJ Specialized Hospital, Gazipur, Bangladesh. He is an Executive Committee member of War-on-Cancer Malaysia (WoC), and supports the activities of NGOs like KanWork, National Cancer Society Malaysia (NCSM) and Majlis Kanser Nasional (MAKNA). Finally, he has recently been involved in a few research projects in oncology under the KPJ Healthcare University.

Prostate cancer is the third most common cancer among adult males in Malaysia (Malaysia National Cancer Registry 2012-2016). The data from the Registry also shows more men presenting at an advanced stages of the disease (Stage 3 and 4) compared to an earlier period (2007-2011). Therefore, screening for Malaysian men above 50 years of age is advocated to detect the cancer at an earlier, curable stage.

Radiotherapy is a very effective, non-surgical curative treatment for early stage localised prostate cancer. It offers similar cure rates to prostatectomy, with fewer long-term sexual side effects and little effect on urinary continence. Stereotactic body radiation therapy (SBRT) is a technologically advanced, high-precision radiation treatment that delivers large, daily doses of radiation to the prostate gland in a small number of fractions. To achieve this, advanced imaging modalities like magnetic resonance imaging and prostate specific membrane antigen positron emission tomography (PSMA-PET) are used in combination with cutting-edge radiotherapy planning, imaging and delivery technology.

This will maximise the radiation dose to the prostate cancer and cure rates, while minimising doses to normal tissues, thus significantly lowering toxicities and side effects of treatment. Several studies have demonstrated the safety and efficacy of SBRT for prostate cancer, similar to other radiation therapy techniques. SBRT will ablate malignant tissue in just five treatments delivered over 1–2 weeks. This accelerated scheduling is appealing to patients due to its convenience over the traditional course of radiation that takes 5 to 8 weeks of daily treatments. Majority of studies using SBRT indicated that the 5-year biochemical (prostate specific antigen, PSA) progression free survival for patients with low-, intermediate-, and high-risk localised prostate cancer was 95%, 84% and 81%, respectively.

Urinary changes, bowel changes, and fatigue are common side effects of SBRT to the prostate which are usually short term and reversible. There is also the entity called oligometastatic prostate cancer, a subgroup of patients with a limited number of detectable metastases (1-5 sites, usually bone and nodal metastases), and still being a curable disease. SBRT directed to the prostate cancer and metastatic sites on PSMA-PET scan is a potentially curative treatment option for these patients, together with systemic treatment like hormone therapy and chemotherapy to eradicate micro metastatic disease. SBRT is also a very promising salvage treatment option for intraprostatic recurrence post conventional radiotherapy and post-prostatectomy prostate bed recurrence.

At KPJ Damansara Cancer & Radiosurgery Centre, the state-of-the-art radiotherapy system, the ELEKTA VERSA HD Linear Accelerator (LINAC), was installed and operational in December 2021. This new technology is one of the most cutting-edge radiotherapy systems, allowing advanced radiation treatments like SBRT to be delivered with high precision and short treatment time, improving cure rates and making it very convenient and comfortable for our cancer patients.
The early experience of SBRT for prostate cancer at our centre will be presented. Three patients will be described, 2 patients with early stage, localised prostate cancer (62 ad 76 years old), and 1 patient with oligometastatic prostate cancer (65 years old).

Short term outcomes in terms of biochemical (PSA) control, imaging and toxicity of treatment will also be presented. The SBRT protocol used at our centre delivering the dose of 35 Gy in 5 Fractions over 1 to 2 weeks to the prostate gland and seminal vesicles is very well tolerated by our patients and give excellent short-term outcomes.

SYMPOSIUM 7 Clinical Niche 2
Pursuing A Better Future for People Living with Blood Cancers

Dr. Nur Adila Anuar graduated with an MBBS and Masters in Internal Medicine, both from the University of Malaya. Prior to joining private practice, Dr Nur Adila served at University of Malaya Medical Centre (UMMC) and University of Malaya Specialist Centre (UMSC) as a Senior lecturer and Consultant Physician/Haematologist.

Dr. Nur Adila played an active role in Malaysian medical research, publishing several high impact research papers, and was invited to speak at local and international events. She currently holds a Fellowship in Haematology at the Malaysian Society of Haematology where she received her Certificate of Specialist Training in Haematology.

Her early roots in medical research continue to drive her passion to stay up to date on the latest medical developments in her field and provide the best options for those under her care.

YBhg. Datuk Syed Mohamed Bin
Syed Ibrahim

Prof. Emerita Tan Sri Dato’ Seri
Dr. Sharifah Hapsah Syed Hasan Shahabudin

Zuhalini Zainal

Dashvinder Sidhu

Intan Shasya Liana Zaine

Michael Giuliano

Associate Prof. Dr. Meong-Hi Son

Hiro Park Sung Ho

Mohamed Ridza Bin Mohamed Abdulla

Fahri Azzat

Dr. Mohd Lutfi Fadil Lokman

Professor Dr. Tan Ching Siang

Professor Datuk Dr. A. Rahman A. Jamal

Prof. Emeritus Dato’ Dr. Lokman Saim

Dr. Dinesh Chhetri

Assoc. Prof. Dr. Izdihar Kamal

Sumaria Abd. Moin

Adam Lutfi Abdul Nasir

Nurul Afiqah Heffny

Prof. Dr. Maie St. John

YBhg. Datuk Md Arif Mahmood

Andy David

Clinical Assoc. Prof.
Dr. Steven Wong Bak Siew

Dr. Ravi Bickram Shrestha

Prof. Dr. Tunku Kamarul Zaman Bin Tunku Zainol Abidin

Dr. Imelda Nasreen Nasruddin @Balchin

Dr. Aminudin Rahman Mohd Mydin

Dr. Nur Adila Anuar

CONTACT US

YBhg. Datuk Syed Mohamed Bin Syed Ibrahim

Prof. Emerita Tan Sri Dato’ Seri Dr. Sharifah Hapsah Syed Hasan Shahabudin